EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams

EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams

The European Medicines Agency (EMA) has announced its latest drug approvals, including new active substances and indications. This update provides critical intelligence for pharmaceutical business development teams and investors tracking market catalysts. With the EMA’s Committee for Medicinal Products for Human Use (CHMP) issuing monthly recommendations, January’s decisions carry outsized weight for competitive positioning and deal strategy across Europe.

Key Takeaways from January’s EMA Approvals

• The EMA recommended 104 medicines for marketing authorisation across 2025, with 38 containing new active substances — a key signal of innovation density for BD teams scouting acquisition targets [source].
• January—February 2026 saw continued momentum in new medicine approvals, underscoring the EMA’s sustained pace of centralised evaluations [source].
• The CHMP recommended 15 new indications for already-authorised EU medicines and 1 new generic, expanding therapeutic options and competitive pressure in established classes [source].
• Biosimilar approvals in the VEGF-A and PIGF inhibitor classes were recorded during January—February 2025, signaling growing biosimilar penetration in ophthalmology and oncology-adjacent markets [source].
• New active substance approvals create near-term windows for in-licensing and co-commercialisation deals before originator launch infrastructure is fully established.

Detailed Breakdown of January’s European Medicines Agency Decisions

Each month, the EMA publishes an updated list of medicines for human use currently under evaluation by the CHMP to obtain a marketing authorisation in the EU [source]. The CHMP meets monthly, and its evaluations of marketing authorisation applications submitted through the centralised procedure provide the basis for European Commission drug approvals.

The EMA is responsible for the scientific evaluation of centralised procedures, meaning that CHMP positive opinions typically translate into formal European Commission authorisations within 67 days [source]. In 2025, the agency recommended 104 medicines for marketing authorisation, 38 of which had a new active substance — a proportion of roughly 36.5% that reflects the balance between true innovation and lifecycle management [source].

January’s CHMP recommendations included a mix of new active substances, new indications for previously approved therapies, biosimilars, and generics. The authorisation of 15 new indications for existing EU medicines suggests that originator companies are aggressively pursuing label expansions to defend market share ahead of biosimilar and generic entry [source]. The single new generic recommendation, while modest in number, adds incremental competitive pressure in its respective therapeutic class.

Biosimilar approvals recorded during January—February 2025 included products targeting VEGF-A (vascular endothelial growth factor A) and PIGF (phosphatidylinositol-glycan) pathways, areas with significant revenue at stake in retinal disease and oncology [source]. For BD teams, these biosimilar entries represent both a competitive threat to originator franchises and a potential partnering opportunity for companies seeking European market access without de novo development.

Strategic Implications for Pharmaceutical Business Development

The January EMA approvals reshape competitive dynamics in several therapeutic areas simultaneously. New active substance approvals create the most immediate BD opportunity: companies with recently approved but not yet launched assets often seek European commercialisation partners, co-promotion agreements, or regional out-licensing deals to accelerate market entry.

The 15 new indications authorised for existing medicines carry a different strategic signal. These label expansions extend the commercial life of established products and can delay biosimilar erosion. For firms competing in the same indication, these expanded labels raise the bar for market entry and may require head-to-head differentiation data in future registrational trials. BD teams at challenger companies should reassess their competitive positioning in affected therapeutic areas and consider whether pipeline assets need redesign or reprioritisation.

Biosimilar approvals in the VEGF-A and PIGF classes introduce pricing pressure that will ripple through procurement and formulary decisions across EU member states. Originator companies facing biosimilar competition may become more receptive to out-licensing their mature assets or entering supply agreements with pharmacy benefit managers. Conversely, biosimilar manufacturers with EMA authorisations are well-positioned for partnerships with hospital groups and national health systems seeking cost-effective alternatives.

M&A implications are also notable. Companies holding newly approved active substances with limited European commercial infrastructure become attractive acquisition targets for mid-cap pharma firms seeking to build EU presence. Private equity investors tracking EMA approvals can identify platform opportunities in the 12—24 months post-authorisation window, when valuations may not yet fully reflect commercial potential.

Investor Outlook on Recent EMA Approvals

For investors, EMA approvals function as discrete valuation catalysts. Each CHMP positive opinion reduces regulatory risk and narrows the timeline to revenue generation. The 38 new active substances approved in 2025 represent a pipeline of potential revenue inflection points across the next 18 months, assuming standard European pricing and reimbursement timelines.

The pace of approvals matters as much as the absolute number. EMA approvals for new medicines recorded in January—February 2026 indicate that the agency has maintained its evaluation cadence into the new year [source]. Investors should monitor whether this pace accelerates or decelerates as the year progresses, as it serves as a leading indicator of near-term commercial catalysts across European-listed pharma equities.

Biosimilar approvals carry asymmetric investment implications. For biosimilar manufacturers, EMA authorisation unlocks access to a multi-billion-euro European market. For originator companies with exposed franchises, biosimilar entry triggers revenue decline assumptions that are often priced in gradually rather than abruptly. Investors with concentrated positions in originator VEGF-A or PIGF inhibitors should model biosimilar penetration scenarios based on historical European uptake curves, which typically show 20—40% market share capture within the first 12 months post-launch.

The 15 new indications approved for existing products offer a more nuanced investment signal. These approvals extend revenue duration for originator companies but may also indicate that the approved therapies are approaching the end of their innovation cycle, relying on label expansion rather than novel molecule development to sustain growth. Investors should cross-reference new indication approvals with pipeline disclosure to assess whether originator R&D productivity is keeping pace with lifecycle management needs.

Key Takeaways

• The EMA recommended 104 medicines for marketing authorisation in 2025, with 38 new active substances driving innovation-weighted deal flow [source].
• Fifteen new indications for already-authorised medicines and 1 new generic were recommended by the CHMP, intensifying competitive pressure in established therapeutic classes [source].
• Biosimilar approvals in VEGF-A and PIGF inhibitor classes signal growing pricing pressure in ophthalmology and adjacent markets [source].
• January 2026 approvals confirm the EMA’s sustained evaluation pace, providing a steady cadence of investment catalysts [source].
• BD teams should prioritise newly approved assets with limited EU commercial infrastructure as near-term licensing and acquisition targets.

Frequently Asked Questions

Related coverage

• CHMP Approves New Medicines: Key Decisions and Implications for the Pharmaceutical Industry
• SFEE Highlights Significant Delays in Greek Patient Access to New Medicines
• European Commission Opens 2026 Joint Scientific Consultation Submission Window